195 related articles for article (PubMed ID: 37933083)
1. A Metabolic Gene Survey Pinpoints Fucosylation as a Key Pathway Underlying the Suppressive Function of Regulatory T Cells in Cancer.
Pinioti S; Sharma H; Flerin NC; Yu Q; Tzoumpa A; Trusso Cafarello S; De Bousser E; Callewaert N; Oldenhove G; Schlenner S; Thienpont B; Garg AD; Di Matteo M; Mazzone M
Cancer Immunol Res; 2023 Dec; 11(12):1611-1629. PubMed ID: 37933083
[TBL] [Abstract][Full Text] [Related]
2. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
Revenko A; Carnevalli LS; Sinclair C; Johnson B; Peter A; Taylor M; Hettrick L; Chapman M; Klein S; Solanki A; Gattis D; Watt A; Hughes AM; Magiera L; Kar G; Ireland L; Mele DA; Sah V; Singh M; Walton J; Mairesse M; King M; Edbrooke M; Lyne P; Barry ST; Fawell S; Goldberg FW; MacLeod AR
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35387780
[TBL] [Abstract][Full Text] [Related]
3. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
4. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.
Cohen AD; Schaer DA; Liu C; Li Y; Hirschhorn-Cymmerman D; Kim SC; Diab A; Rizzuto G; Duan F; Perales MA; Merghoub T; Houghton AN; Wolchok JD
PLoS One; 2010 May; 5(5):e10436. PubMed ID: 20454651
[TBL] [Abstract][Full Text] [Related]
5. Reduced frequency and functional defects of CD4
Luo L; Zeng X; Huang Z; Luo S; Qin L; Li S
Reprod Biol Endocrinol; 2020 Jun; 18(1):62. PubMed ID: 32522204
[TBL] [Abstract][Full Text] [Related]
6. Remodeling of the tumor microenvironment via disrupting Blimp1
Dixon ML; Luo L; Ghosh S; Grimes JM; Leavenworth JD; Leavenworth JW
Mol Cancer; 2021 Nov; 20(1):150. PubMed ID: 34798898
[TBL] [Abstract][Full Text] [Related]
7. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
8. Foxp3(+) T cells expressing RORγt represent a stable regulatory T-cell effector lineage with enhanced suppressive capacity during intestinal inflammation.
Yang BH; Hagemann S; Mamareli P; Lauer U; Hoffmann U; Beckstette M; Föhse L; Prinz I; Pezoldt J; Suerbaum S; Sparwasser T; Hamann A; Floess S; Huehn J; Lochner M
Mucosal Immunol; 2016 Mar; 9(2):444-57. PubMed ID: 26307665
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma.
Mougiakakos D; Johansson CC; Trocme E; All-Ericsson C; Economou MA; Larsson O; Seregard S; Kiessling R
Cancer; 2010 May; 116(9):2224-33. PubMed ID: 20209608
[TBL] [Abstract][Full Text] [Related]
10. FOXP3 (in)stability and cancer immunotherapy.
Mortezaee K
Cytokine; 2024 Jun; 178():156589. PubMed ID: 38547750
[TBL] [Abstract][Full Text] [Related]
11. ＜Editors' Choice＞ Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity.
Kochin V; Nishikawa H
Nagoya J Med Sci; 2019 Feb; 81(1):1-18. PubMed ID: 30962651
[TBL] [Abstract][Full Text] [Related]
12. CD4⁺ T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer.
Mahalingam J; Lin CY; Chiang JM; Su PJ; Chu YY; Lai HY; Fang JH; Huang CT; Lin YC
PLoS One; 2014; 9(9):e108554. PubMed ID: 25268580
[TBL] [Abstract][Full Text] [Related]
13. Treg plasticity and human diseases.
Zhang Z; Guo J; Jia R
Inflamm Res; 2023 Dec; 72(12):2181-2197. PubMed ID: 37878023
[TBL] [Abstract][Full Text] [Related]
14. Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity.
Yan Y; Huang L; Liu Y; Yi M; Chu Q; Jiao D; Wu K
J Hematol Oncol; 2022 Aug; 15(1):104. PubMed ID: 35948909
[TBL] [Abstract][Full Text] [Related]
15. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
[TBL] [Abstract][Full Text] [Related]
16. Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions.
Li X; Acuff NV; Peeks AR; Kirkland R; Wyatt KD; Nagy T; Watford WT
J Biol Chem; 2016 Aug; 291(32):16802-15. PubMed ID: 27261457
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the MT-2 Treg-like cell line in the presence and absence of forkhead box P3 (FOXP3).
McCullough MJ; Tune MK; Cabrera JC; Torres-Castillo J; He M; Feng Y; Doerschuk CM; Dang H; Beltran AS; Hagan RS; Mock JR
Immunol Cell Biol; 2024 Mar; 102(3):211-224. PubMed ID: 38288547
[TBL] [Abstract][Full Text] [Related]
18. Development and function of FOXP3+ regulators of immune responses.
Golzari-Sorkheh M; Zúñiga-Pflücker JC
Clin Exp Immunol; 2023 Jul; 213(1):13-22. PubMed ID: 37085947
[TBL] [Abstract][Full Text] [Related]
19. YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.
Ni X; Tao J; Barbi J; Chen Q; Park BV; Li Z; Zhang N; Lebid A; Ramaswamy A; Wei P; Zheng Y; Zhang X; Wu X; Vignali P; Yang CP; Li H; Pardoll D; Lu L; Pan D; Pan F
Cancer Discov; 2018 Aug; 8(8):1026-1043. PubMed ID: 29907586
[TBL] [Abstract][Full Text] [Related]
20. Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application.
Henschel P; Landwehr-Kenzel S; Engels N; Schienke A; Kremer J; Riet T; Redel N; Iordanidis K; Saetzler V; John K; Heider M; Hardtke-Wolenski M; Wedemeyer H; Jaeckel E; Noyan F
J Autoimmun; 2023 Jul; 138():103057. PubMed ID: 37224732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
